首页> 外文期刊>Transfusion and apheresis science: official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis >'Reasonable compromise' to define the quality standards of platelet concentrate for non-transfusion use (CPunT)
【24h】

'Reasonable compromise' to define the quality standards of platelet concentrate for non-transfusion use (CPunT)

机译:“合理的妥协”,以定义血小板浓缩物质量标准,用于非输注使用(计数)

获取原文
获取原文并翻译 | 示例
           

摘要

Platelets concentrate for non-transfusion use (CPunT) is a blood component specific for regenerative medicine. This blood component has found regenerative applications in many clinical fields (orthopedic, plastic surgery, maxillofacial surgery) since platelets contain growth factors, cytokines and bioactive molecules. Plasticity and ease of preparation of this blood component has often led the user to prepare it without using standardized procedures and references to quality product standards, but to evaluate the effectiveness of treatments and to standardize clinical protocols, is essential. The complexity of establish functional and non-functional parameters to define CPunT properties is linked to three fundamental steps: variability and bioavailability of biomolecules content in platelets, variability in product preparation. Then it is very difficult to understand which are the real parameters to evaluate, but it seems a "reasonable compromise" to establish content of platelets×ml (1×109ml) as reference realistic parameter for CPunT qualification.
机译:用于非输血使用的血小板浓缩物(CPINK)是一种针对再生药物的血液组分。这种血液成分在许多临床领域(整形外科,整形手术,颌面外科)发现再生应用,因为血小板含有生长因子,细胞因子和生物活性分子。这种血液成分的可塑性和易于准备通常导致用户在不使用标准化程序和优质产品标准的参考文献的情况下使用户进行制备,而是评估治疗的有效性和标准化临床方案,这是必不可少的。建立功能和非功能参数的复杂性与三个基本步骤相关联:血小板中生物分子含量的可变性和生物利用度,产品制备的可变性。然后很难理解哪些是评估的真实参数,但似乎是“合理的折衷”,建立血小板×ml(1×109ml)的内容作为CPInd资格的参考现实参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号